EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

Teng-Li Lin, Yi-Hsuan Fan, Kuo-Sheng Fan, Chao-Kuei Juan, Yi-Ju Chen, Chun-Ying Wu

JAMA Dermatology · 01.08.2025 · 161 (8) · 813

DOI: 10.1001/jamadermatol.2025.1578 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA Dermatology, erschienen am 01.08.2025. Verfasst von Teng-Li Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Psoriasis, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Patients with atopic dermatitis (AD) have been reported to develop psoriasis during dupilumab treatment. Whether this represents a true association or an incidental event remains unclear.

Objective

To compare psoriasis risk in patients with AD who are prescribed dupilumab vs other systemic agents. Design, Setting, and Participants This population-based retrospective cohort study with 3-year follow-up, with analyses completed on October 19, 2024, included 214 430 adult patients with AD from the TriNetX Global Collaborative Network. Individuals newly prescribed dupilumab (dupilumab cohort) and those newly prescribed the other systemic agents without dupilumab exposure (control cohort) were included. Propensity score matching at a 1:1 ratio based on age, sex, race, comorbidities, laboratory measurements, and prior medications was conducted. Exposures Dupilumab vs the other systemic agents (corticosteroids, methotrexate, cyclosporine, azathioprine, or mycophenolate mofetil). Main Outcomes and Measures The primary outcome was incident psoriasis. Cumulative incidence was assessed using Kaplan-Meier plots and risks via Cox regression.

Results

After matching, each cohort comprised 9860 patients, with 10 891 female individuals (55.2%), a mean (SD) age of 44.8 (20.3) years, 3582 African American or Black individuals (18.2%), 2004 Asian individuals (10.2%), and 9901 White individuals (50.2%). The 3-year cumulative psoriasis incidence was higher in the dupilumab cohort than the control cohort (2.86% vs 1.79%; P < .001). The number needed to harm for psoriasis was 94 for dupilumab vs the other systemic agents. The dupilumab cohort showed an increased risk for psoriasis (hazard ratio [HR], 1.58; 95% CI, 1.25-1.99), although the risk for psoriatic arthritis was not significant (HR, 1.97; 95% CI, 0.75-5.18). This increased risk was also observed in various AD subgroups, including those without atopic comorbidities (HR, 1.42; 95% CI, 1.06-1.89) or with pretreatment immunoglobulin E levels less than 0.048 mg/dL (to convert to mg/L, multiply by 10; HR, 1.59; 95% CI, 1.26-2.01). The association between dupilumab and psoriasis was further supported by validation in patients with asthma without AD (HR, 2.13; 95% CI, 1.38-3.31). Conclusions and Relevance The results of this cohort study suggest that patients with AD who were prescribed dupilumab exhibited a higher relative risk of developing psoriasis compared with those receiving other systemic agents. Given an estimated number needed to harm of 94, the absolute risk may have limited clinical relevance and should be weighed against dupilumab’s established efficacy in treating AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicPsoriasisAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansFemaleMaleAdultRetrospective StudiesMiddle AgedIncidenceFollow-Up StudiesRisk Factors

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.
  • PhD Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Division of Chest Medicine, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.
  • Department of Dermatology, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.

Zitieren

APA

Lin, T. L., Fan, Y. H., Fan, K. S., Juan, C. K., Chen, Y. J., & Wu, C. Y. (2025). Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab. JAMA Dermatology, 161(8), 813. https://doi.org/10.1001/jamadermatol.2025.1578

Vancouver

Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab. JAMA Dermatology. 2025;161(8):813. doi:10.1001/jamadermatol.2025.1578

BibTeX
@article{Lin2025,
  author = {Lin, Teng-Li and Fan, Yi-Hsuan and Fan, Kuo-Sheng and Juan, Chao-Kuei and Chen, Yi-Ju and Wu, Chun-Ying},
  title = {Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab},
  journal = {JAMA Dermatology},
  year = {2025},
  volume = {161},
  number = {8},
  pages = {813},
  doi = {10.1001/jamadermatol.2025.1578}
}
Kostenlos starten →